Status:
COMPLETED
Molecular and Cellular Characterization of Spongiotic Dermatitis
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Atopic Dermatitis
Psoriasis
Eligibility:
All Genders
18-55 years
Brief Summary
Spongiotic dermatitis is the histopathologic diagnosis commonly issued by dermatopathologists that encompasses atopic dermatitis, contact dermatitis, and other forms of eczematous dermatitis. The inf...
Detailed Description
Spongiotic dermatitis is the histopathologic diagnosis commonly issued by dermatopathologists that encompasses atopic dermatitis, contact dermatitis, and other forms of eczematous dermatitis. Atopic d...
Eligibility Criteria
Inclusion
- Atopic Dermatitis: Subjects will be identified based on the Hanifin criteria of atopic dermatitis. Subjects will be adults with a history of atopic dermatitis since childhood, who continue to have symptoms and signs of atopic dermatitis. They must have active lesions and should not be on systemic therapy.
- Contact Dermatitis: Subjects will be adults with history of contact dermatitis to common allergens. They will undergo patch testing to common allergens and the sites of positive reactions will be considered as lesional skin.
- Psoriasis: Subjects will be adults with chronic disease, who have active skin lesions with a characteristic morphology.
- Subjects will be asked to discontinue topical medications at least to parts of the skin where biopsies will be taken, one week prior to biopsy.
- \-
Exclusion
- Patients on systemic treatment of their skin diseases within the past one month.
- A history of significant neurologic, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic diseases.
- Abnormal hepatic function or renal function (creatinine or BUN is \> 1.2 times the upper level of the normal range for the laboratory where the testing is done).
- Abnormal blood counts (WBC \< 4 x 103/mm3; platelet \< 100 x 103/mm3; hemoglobin \< 11g/dl).
- History of alcohol or drug abuse.
- Known hepatitis or HIV.
- Pregnant women (as determined by serum pregnancy test).
- Significant allergic or adverse reaction to local anesthetics.
- Blood clotting disorder.
- Faintness or vasovagal reaction with blood draws or procedures.
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00371163
Start Date
September 1 2006
End Date
December 1 2012
Last Update
April 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis Department of Dermatology
Sacramento, California, United States, 95816